Navigation Links
VIVUS Reports Topline Findings From FORTRESS
Date:12/21/2011

MOUNTAIN VIEW, Calif., Dec. 21, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced topline preliminary results from its retrospective study of medical claims data on oral clefts (OC) associated with topiramate exposure in utero.  The study, known as FORTRESS for Fetal Outcome Retrospective TopiRamate ExpoSure Study, identified 1,945 mother-infant dyads exposed to topiramate either alone (monotherapy) or in combination with other antiepileptic agents (polytherapy) in the first trimester of pregnancy (the "Total Topiramate Cohort"). Among the Total Topiramate Cohort, 1,740 dyads were exposed to topiramate monotherapy (the "Topiramate Monotherapy Cohort"). There were 5 oral clefts in the Topiramate Monotherapy Cohort for a prevalence rate of 0.29% (5/1,740).  This prevalence rate was compared to a control group of infants of women who had previously taken antiepileptic drugs including topiramate but not during the pregnancy of interest (the "Formerly Exposed Cohort").  The prevalence rate for the Formerly Exposed Cohort was 0.16% (21/13,512). The prevalence ratio for Topiramate Monotherapy Cohort versus the Formerly Exposed Cohort was 1.88 (center-standardized, 95% CI 0.70–5.03).

"The prevalence ratio for oral clefts in FORTRESS is within the recently reported range for topiramate from several large studies," commented Peter Tam, president of VIVUS, Inc.  "We have shared these results with the FDA. We continue to work closely with the FDA during their review of the NDA and as we prepare for the upcoming Advisory Committee meeting expected in the first quarter of 2012."

The FORTRESS study analyzed data from the Total Topiramate Cohort, the Formerly Exposed Cohort, and a second control group, infants of women with similar medical profiles to the Total Topiramate Cohort regardless of prior antiepileptic drug use (t
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. VIVUS to Present at the Credit Suisse 2011 Healthcare Conference
2. VIVUS Resubmits Qnexa NDA to the FDA
3. VIVUS Provides Regulatory Update on QNEXA
4. VIVUS Announces FDA Acceptance of Avanafil New Drug Application for Treatment of Erectile Dysfunction
5. VIVUS Announces $45.8 Million Registered Direct Offering of Common Stock
6. VIVUS Reports Second Quarter and First Six Months 2011 Financial Results
7. VIVUS Reports 2010 Fourth Quarter and Full-Year Financial Results
8. VIVUS to Present at Three Upcoming Investor Conferences in March
9. VIVUS Provides Regulatory Update on QNEXA NDA
10. VIVUS to Present at the 2011 JP Morgan Healthcare Conference
11. VIVUS Submits Briefing Document to FDA, Announces Follow-up Meeting to Discuss QNEXA®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Inc., a leader in hand hygiene monitoring, today announced ... subsidiary of Ascendis Health Limited, in Johannesburg, ... of millions of patients around the world are affected ... patient to patient via the unwashed hands of healthcare ...
(Date:1/23/2015)... , Jan. 23, 2015 Cord Blood America, Inc. ( ... or the "Company")  filed a Preliminary Proxy Statement, Schedule 14A, ... today, and provides an update for shareholders detailing why a ... requested. Dear Shareholders, As we reflect ...
(Date:1/23/2015)... , Jan. 23, 2015 Gem Pharmaceuticals announced today ... been enrolled into the Company,s Phase 2 clinical trial. ... of Gem,s lead compound, GPX-150 (an investigational medication), in ... metastatic disease. Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
Breaking Medicine Technology:HyGreen Partners with RCA Medical in Johannesburg, South Africa 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2
... Australia--(BUSINESS WIRE)--Jul 5, 2007 - Australian,biotechnology company Avexa ... blinded phase which,represents the first 24 week segment ... into the open-label section of the,trial (weeks 24 ... twice a day as part of their daily ...
... LAINATE, Italy - July 4, 2007 - Cosmo ... its,phase II/III study with CB-01-11 (Rifamycin SV MMX(tm)) ... that is not absorbed when taken in tablet ... delivers the active,ingredient into the colon, bacteria in ...
Cached Medicine Technology:Avexa's Apricitabine Clinical Trial Update 2Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III,Data with Rifamycin MMX in Infectious Diarrhea 2
(Date:1/22/2015)... (PRWEB) January 22, 2015 Juvent Sports ... at the 2015 PGA Merchandise Show to bestow a ... incredible female amateur golfer, Arlene McKitrick. The award commemorated ... amateur golf tournament win. She won her first amateur ...
(Date:1/22/2015)... Autocarinsurancebest.com has released a new blog post ... insurance policy . , Auto insurance quotes help many ... no longer necessary to call an agent or visit an ... on a single website: http://autocarinsurancebest.com/ . , Every business ...
(Date:1/22/2015)... NJ (PRWEB) January 22, 2015 Joan ... and keynote speaker at the upcoming 32nd Annual ... ACCME-accredited Physicians’ Education Resource®, LLC (PER®) , shares ... would have gone undetected if she had not followed ...
(Date:1/22/2015)... 23, 2015 Recently, Weddingshe.com has added many ... has announced its highest annual revenues in the past three ... popular glamorous wedding dresses. , According to the sales manager ... dress promotions for them in 2015. This point can be ...
(Date:1/22/2015)... January 22, 2015 Payday lending practices ... communities and cause financial distress to the states that ... at Howard University’s Center on Race and Wealth. , ... economic activity, payday loans at the same time substantially ...
Breaking Medicine News(10 mins):Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2
... April 24 Choice Hotels,International (Choice) announced today ... insurance plan from Planned Administrators Inc.,(PAI), available to ... With the announcement, the franchisees that own ... in the United States now have the option ...
... 24 Boston Scientific,Corporation (NYSE: BSX ... the,Multicenter Automatic Defibrillator Implantation Trial with Cardiac,Resynchronization ... examines the potential benefits of Boston Scientific ... population of,heart failure patients. It is the ...
... Research Confirms Rounder Teeth Provide More Feminine and Youthful ... ... dentist Denise,Fundora, DDS ( http://www.fundoradental.com ) of Beverly Hills, CA states,"Changing the ... as rejuvenate your overall appearance. Some of my patients,say that a smile ...
... Their Computerized,Prescribing Systems Are Effective, First Use ... Survey, WASHINGTON, April 24 With the ... becomes the,first health care quality organization to add ... computerized medication prescribing systems are actually,catching common, serious ...
... of cancer, study warns , , THURSDAY, April 24 (HealthDay ... been successfully treated if ovarian or testicular tissue they ... back into their bodies without it being adequately checked ... , Researchers at two university hospitals in Israel, writing ...
... 24 Life Brokerage Partners,announces three additional carrier ... Polaris and United National Finance,Inc. ("UNF"). These premium ... they provide new methods for transacting,business., The ... and UNF,do not end with the agents, but ...
Cached Medicine News:Health News:Choice Hotels Selects PAI as Qualified Vendor to Offer Health Benefits to Part-Time, Hourly Workers in Its Franchisee Base 2Health News:Choice Hotels Selects PAI as Qualified Vendor to Offer Health Benefits to Part-Time, Hourly Workers in Its Franchisee Base 3Health News:Boston Scientific Completes Enrollment in Landmark Heart Failure Trial 2Health News:Boston Scientific Completes Enrollment in Landmark Heart Failure Trial 3Health News:'Size Does Matter ... and So Does Shape ... When It Comes to Teeth,' Says Cosmetic Dentist, Dr. Denise Fundora 2Health News:The Leapfrog Group Releases 2008 Hospital Survey Offering Consumers Greater Assurance of Safety 2Health News:The Leapfrog Group Releases 2008 Hospital Survey Offering Consumers Greater Assurance of Safety 3Health News:The Leapfrog Group Releases 2008 Hospital Survey Offering Consumers Greater Assurance of Safety 4Health News:Stored Ovarian Tissue Needs Testing Before Re-Implantation 2Health News:Life Brokerage Partners Strengthens Premium Finance Programs 2
... Perfectly balanced, the patented Orion incorporates ... that illuminates brilliantly. The fully adjustable ... designed to sit low on the brow, ... vision. Two clips on the headband ...
Latex-free coronary artery perfusion/cardioplegia infusion cannulae....
... OXYPLETH is seven pounds of ... technology combined with software developed over ... team provides the ultimate in non-invasive ... unique oximeter monitor technology and sophisticated ...
... The ODISsey Tissue Oximeter is a lightweight, ... LCD display monitor with two separate channels for ... and cables as well as adjustable alarms for ... The system is very user friendly and requires ...
Medicine Products: